niacinamide has been researched along with Angina Pectoris in 53 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antianginal activities of nicorandil, 10 and 20 mg bid, and metoprolol, 100 mg bid, were compared in patients with stable effort angina pectoris in a randomized, double-blind parallel group study lasting 7 weeks." | 9.07 | A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. ( Bokor, D; Carotenuto, A; de Divitiis, M; de Divitiis, O; Di Somma, S; Liguori, V; Petitto, M, 1993) |
| "Patients with stable, effort-induced angina pectoris and a typical combination of anginal pain and ischemic ST depression in exercise tolerance tests were randomized to treatment for 8 weeks with nicorandil (a newly developed antianginal and anti-ischemic drug) or nifedipine." | 9.07 | Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. ( Diderholm, E; Frithz, G; Gudbrandsson, T; Hedbäck, B; Höglund, C; Moelstad, P; Perk, J; Sverrisson, JT; Ulvenstam, G, 1992) |
| "Nicorandil therapy was compared with placebo therapy in 11 patients with chronic stable angina pectoris." | 9.06 | Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. ( Bito, K; Itoh, M; Kawakita, S; Kinoshita, M; Mashiro, I; Mitsunami, K; Motomura, M; Nishikawa, S; Sawamura, M; Yamaguchi, S, 1986) |
| "To elucidate the effect of Nicorandil on myocardial energy metabolism and myocardial sympathetic activity, we administered Nicorandil orally to eight patients with angina pectoris prior to exercise testing." | 7.69 | Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris. ( Hisatome, I; Kato, M; Kinugawa, T; Kitamura, H; Matsumoto, T; Miyakoda, H; Noguchi, N; Ogino, K; Omodani, H; Osaki, S, 1995) |
| "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem." | 7.69 | Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis. ( Araki, H; Higuchi, S; Kishi-Tanikawa, S; Takahashi, K; Takahashi, T; Tsuchida, K, 1996) |
| "Nicorandil treatment did not change the altered heart rate variability in either time domain or spectral analysis." | 6.68 | Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. ( Chang, MS; Chen, JW; Hsu, NW; Lee, WL; Lin, SJ; Ting, CT; Wang, SP, 1997) |
| "Nicorandil is a potent coronary vasodilator." | 6.67 | Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. ( Bucx, JJ; Henneman, JA; Hugenholtz, PG; Kelder, JC; Kerker, JP; Meeter, K; Tijssen, JG, 1992) |
| "Nicorandil is a vasodilator that acts on the venous and arterial beds of the systemic circulation." | 6.66 | A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. ( Camm, AJ; Maltz, MB, 1989) |
| "This randomized, double-blind, parallel study compared the anti-anginal effects of nicorandil and atenolol in 37 patients with exercise-induced angina pectoris." | 5.07 | A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. ( Hughes, LO; Lahiri, A; Raftery, EB; Rose, EL, 1993) |
| "The antianginal activities of nicorandil, 10 and 20 mg bid, and metoprolol, 100 mg bid, were compared in patients with stable effort angina pectoris in a randomized, double-blind parallel group study lasting 7 weeks." | 5.07 | A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. ( Bokor, D; Carotenuto, A; de Divitiis, M; de Divitiis, O; Di Somma, S; Liguori, V; Petitto, M, 1993) |
| "Patients with stable, effort-induced angina pectoris and a typical combination of anginal pain and ischemic ST depression in exercise tolerance tests were randomized to treatment for 8 weeks with nicorandil (a newly developed antianginal and anti-ischemic drug) or nifedipine." | 5.07 | Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. ( Diderholm, E; Frithz, G; Gudbrandsson, T; Hedbäck, B; Höglund, C; Moelstad, P; Perk, J; Sverrisson, JT; Ulvenstam, G, 1992) |
| "Nicorandil was compared with placebo, propranolol and low and high doses of diltiazem therapy in 12 patients with chronic stable angina pectoris to elucidate its antianginal mechanism." | 5.06 | Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism. ( Hashimoto, K; Inoue, T; Kinoshita, M; Mitsunami, K; Ohbayashi, Y; Taguchi, H, 1989) |
| "Nicorandil therapy was compared with placebo therapy in 11 patients with chronic stable angina pectoris." | 5.06 | Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. ( Bito, K; Itoh, M; Kawakita, S; Kinoshita, M; Mashiro, I; Mitsunami, K; Motomura, M; Nishikawa, S; Sawamura, M; Yamaguchi, S, 1986) |
| "The primary drugs utilized in the treatment of angina pectoris include organic nitrates, beta-adrenoceptor antagonists, Ca2+ antagonists, and the antithrombotic agents aspirin and heparin." | 4.79 | Pharmacologic therapy of angina pectoris. ( Bueno, O; Zavecz, JH, 1995) |
| "Nicorandil (Ikorel-Rhône-Poulenc Rorer; Merck & Lipha) is marketed for the prevention and long-term treatment of angina pectoris." | 4.79 | Nicorandil for angina. ( , 1995) |
| "To elucidate the effect of Nicorandil on myocardial energy metabolism and myocardial sympathetic activity, we administered Nicorandil orally to eight patients with angina pectoris prior to exercise testing." | 3.69 | Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris. ( Hisatome, I; Kato, M; Kinugawa, T; Kitamura, H; Matsumoto, T; Miyakoda, H; Noguchi, N; Ogino, K; Omodani, H; Osaki, S, 1995) |
| "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem." | 3.69 | Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis. ( Araki, H; Higuchi, S; Kishi-Tanikawa, S; Takahashi, K; Takahashi, T; Tsuchida, K, 1996) |
| " Angina pectoris was induced by methacholine or isoproterenol, and the change in the ST-segments in the electrocardiogram (ECG) was used as the parameter to indicate angina pectoris." | 3.68 | Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats. ( Fukata, Y; Fukushima, H; Harada, K; Kaneta, S; Miwa, A; Ogawa, N, 1993) |
| "The effects of a newly developed nicotinamide derivative, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75, Nicorandil), were examined in an experimental model of angina pectoris, utilizing methacholine-induced ECG changes as main parameter in intact anesthetized rats." | 3.66 | Effects of N-(2-hydroxyethyl)nicotinamide nitrate (SG-75) on methacholine-induced ECG changes in intact anesthetized rats. ( Akima, M; Aono, J; Sakai, K, 1981) |
| "Nicorandil is an antianginal drug that causes potent coronary vasodilation of both epicardial and resistance vessels." | 2.68 | Coronary microvascular response to intracoronary administration of nicorandil. ( Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995) |
| "Nicorandil is an effective coronary dilator and is reported to affect both large and small coronary arteries." | 2.68 | [Effects of nicorandil on coronary collateral circulation depend on the donor arteries]. ( Aonuma, K; Hiroe, M; Igawa, M; Inada, M; Korenaga, M; Marumo, F; Ogawara, S; Okamoto, Y; Umezawa, S, 1996) |
| "Nicorandil treatment did not change the altered heart rate variability in either time domain or spectral analysis." | 2.68 | Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. ( Chang, MS; Chen, JW; Hsu, NW; Lee, WL; Lin, SJ; Ting, CT; Wang, SP, 1997) |
| "Nicorandil and diltiazem were both found to decrease the frequency of anginal attacks and the consumption of nitroglycerin tablets (P < 0." | 2.67 | A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. ( Blin, P; Guermonprez, JL; Peterlongo, F, 1993) |
| "Nicorandil is a potent coronary vasodilator." | 2.67 | Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. ( Bucx, JJ; Henneman, JA; Hugenholtz, PG; Kelder, JC; Kerker, JP; Meeter, K; Tijssen, JG, 1992) |
| "Nicorandil is a vasodilator that acts on the venous and arterial beds of the systemic circulation." | 2.66 | A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. ( Camm, AJ; Maltz, MB, 1989) |
| "Nicorandil and placebo were given according to the randomized double-blind method." | 2.66 | Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. ( Araki, H; Hayata, N; Nakamura, M, 1986) |
| "Nicorandil is a balanced arterial and venodilator that may also possess cardioprotective properties via its activation of ATP-sensitive potassium channels." | 2.39 | Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil. ( Fox, K; Knight, C; Purcell, H, 1995) |
| " Clinical trials demonstrate that chronic administration of nicorandil can significantly increase exercise tolerance in patients with coronary artery disease." | 2.38 | [Anti-angina activity of potassium-channel activators]. ( Ambrosio, G; Chiariello, M; Duilio, C, 1993) |
| "Nicorandil has the capacity to increase myocardial oxygen supply without increasing oxygen demand by reduction in preload and afterload." | 2.38 | Nicorandil: animal pharmacology. ( Sakai, K, 1989) |
| "Pretreatment with nicorandil 3 x 10(-7) and 3 x 10(-6) M potentiated the relaxation induced by ISO." | 1.29 | Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase. ( Inoue, M; Morikawa, M; Satake, N; Shibata, S; Zhou, Q, 1995) |
| " Adverse events usually occurred early in the course of treatment." | 1.29 | Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. ( Roland, E, 1993) |
| " When nicorandil in a dosage of 20 to 40 mg/day was added to the regimen, the mean number of attacks dropped significantly (P less than 0." | 1.27 | Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate. ( Araki, H; Hayata, N; Matsuguchi, T; Nakamura, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (33.96) | 18.7374 |
| 1990's | 34 (64.15) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmutz, JL | 1 |
| Trechot, P | 1 |
| Inou, T | 1 |
| Aono, J | 1 |
| Akima, M | 1 |
| Sakai, K | 4 |
| Ogino, K | 1 |
| Osaki, S | 1 |
| Noguchi, N | 1 |
| Kitamura, H | 1 |
| Omodani, H | 1 |
| Kato, M | 1 |
| Hisatome, I | 1 |
| Matsumoto, T | 1 |
| Kinugawa, T | 1 |
| Miyakoda, H | 1 |
| Kaski, JC | 1 |
| Knight, C | 1 |
| Purcell, H | 1 |
| Fox, K | 1 |
| Satake, N | 1 |
| Zhou, Q | 1 |
| Morikawa, M | 1 |
| Inoue, M | 1 |
| Shibata, S | 1 |
| Zavecz, JH | 1 |
| Bueno, O | 1 |
| Ribeiro, C | 1 |
| Hongo, M | 1 |
| Takenaka, H | 1 |
| Uchikawa, S | 1 |
| Nakatsuka, T | 1 |
| Watanabe, N | 1 |
| Sekiguchi, M | 1 |
| Benedini, F | 1 |
| Bertolini, G | 1 |
| Cereda, R | 1 |
| Donà, G | 1 |
| Gromo, G | 1 |
| Levi, S | 1 |
| Mizrahi, J | 1 |
| Sala, A | 1 |
| Shetty, K | 1 |
| Chiariello, M | 1 |
| Duilio, C | 1 |
| Ambrosio, G | 1 |
| Yamazaki, J | 2 |
| Iida, M | 2 |
| Igarashi, M | 1 |
| Hosoi, H | 2 |
| Ishiguro, S | 1 |
| Hou, M | 1 |
| Morishita, T | 2 |
| Nakano, H | 2 |
| Yabe, Y | 2 |
| Koyama, N | 2 |
| Harada, K | 1 |
| Fukata, Y | 1 |
| Miwa, A | 1 |
| Kaneta, S | 1 |
| Fukushima, H | 1 |
| Ogawa, N | 1 |
| Why, HJ | 1 |
| Richardson, PJ | 1 |
| Guermonprez, JL | 1 |
| Blin, P | 1 |
| Peterlongo, F | 1 |
| Raftery, EB | 2 |
| Lahiri, A | 2 |
| Hughes, LO | 2 |
| Rose, EL | 2 |
| Roland, E | 1 |
| Di Somma, S | 1 |
| Liguori, V | 1 |
| Petitto, M | 1 |
| Carotenuto, A | 1 |
| Bokor, D | 1 |
| de Divitiis, O | 1 |
| de Divitiis, M | 1 |
| Ohsawa, H | 1 |
| Uchi, T | 1 |
| Komatsu, H | 1 |
| Ejima, J | 1 |
| Kaneda, K | 1 |
| Moriyama, H | 1 |
| Ohmura, I | 1 |
| Maruyama, T | 1 |
| Kaji, Y | 1 |
| Tsuda, Y | 1 |
| Kanaya, S | 1 |
| Fujino, T | 1 |
| Niho, Y | 1 |
| Takahashi, T | 1 |
| Takahashi, K | 1 |
| Kishi-Tanikawa, S | 1 |
| Tsuchida, K | 1 |
| Araki, H | 3 |
| Higuchi, S | 1 |
| Yamabe, H | 1 |
| Namura, H | 1 |
| Yano, T | 1 |
| Fujita, H | 1 |
| Kim, S | 1 |
| Iwahashi, M | 1 |
| Maeda, K | 1 |
| Yokoyama, M | 1 |
| Umezawa, S | 1 |
| Ogawara, S | 1 |
| Okamoto, Y | 1 |
| Igawa, M | 1 |
| Aonuma, K | 1 |
| Inada, M | 1 |
| Korenaga, M | 1 |
| Hiroe, M | 1 |
| Marumo, F | 1 |
| Specchia, G | 1 |
| Marsico, F | 1 |
| Micheletti, T | 1 |
| Bona, M | 1 |
| Chen, JW | 1 |
| Lee, WL | 1 |
| Hsu, NW | 1 |
| Lin, SJ | 1 |
| Ting, CT | 1 |
| Wang, SP | 1 |
| Chang, MS | 1 |
| Carr, CS | 1 |
| Yellon, DM | 1 |
| Hirata, Y | 1 |
| Miyai, H | 1 |
| Mabuchi, Y | 1 |
| Aisaka, K | 1 |
| Kleiber, G | 1 |
| Leickert, KH | 1 |
| Frampton, J | 1 |
| Buckley, MM | 1 |
| Fitton, A | 1 |
| Meeter, K | 1 |
| Kelder, JC | 1 |
| Tijssen, JG | 1 |
| Bucx, JJ | 1 |
| Henneman, JA | 1 |
| Kerker, JP | 1 |
| Hugenholtz, PG | 1 |
| Ulvenstam, G | 1 |
| Diderholm, E | 1 |
| Frithz, G | 1 |
| Gudbrandsson, T | 1 |
| Hedbäck, B | 1 |
| Höglund, C | 1 |
| Moelstad, P | 1 |
| Perk, J | 1 |
| Sverrisson, JT | 1 |
| Wagner, G | 1 |
| Lai, C | 1 |
| Onnis, E | 1 |
| Solinas, R | 1 |
| Orani, E | 1 |
| Lai, G | 1 |
| Cadeddu, M | 1 |
| Cherchi, A | 1 |
| Kinoshita, M | 3 |
| Kambara, H | 1 |
| Nakamura, Y | 2 |
| Tamaki, S | 1 |
| Kawai, C | 1 |
| Kato, K | 1 |
| Asanoi, H | 1 |
| Wakabayashi, C | 1 |
| Hosoda, S | 1 |
| Shiina, A | 1 |
| Hosono, K | 1 |
| Kurita, A | 1 |
| Seki, K | 1 |
| Ishida, K | 1 |
| Kuroiwa, A | 1 |
| Silke, B | 1 |
| Verma, SP | 1 |
| Ali, MS | 1 |
| Goldhammer, E | 1 |
| Taylor, SH | 1 |
| Camm, AJ | 2 |
| Maltz, MB | 2 |
| Meany, TB | 1 |
| Richardson, P | 1 |
| Coltart, J | 1 |
| Griffith, M | 1 |
| Signy, M | 1 |
| Hashimoto, K | 1 |
| Ohbayashi, Y | 1 |
| Inoue, T | 1 |
| Taguchi, H | 1 |
| Mitsunami, K | 2 |
| Hiasa, Y | 1 |
| Hamai, K | 1 |
| Wada, T | 1 |
| Aihara, T | 1 |
| Bando, M | 1 |
| Nakai, Y | 1 |
| Kataoka, Y | 1 |
| Nishikawa, S | 1 |
| Sawamura, M | 1 |
| Yamaguchi, S | 1 |
| Itoh, M | 1 |
| Motomura, M | 1 |
| Bito, K | 1 |
| Mashiro, I | 1 |
| Kawakita, S | 1 |
| Hayata, N | 2 |
| Nakamura, M | 2 |
| Leitold, M | 1 |
| Hader, S | 1 |
| Matsuguchi, T | 1 |
| Yamazaki, T | 1 |
| Sugimoto, T | 1 |
| Chazov, EI | 1 |
| Smetnev, AS | 1 |
| Petrova, LI | 1 |
| Tabak, VIa | 1 |
| Ivashchenko, AG | 1 |
| Zakin, AM | 1 |
11 reviews available for niacinamide and Angina Pectoris
| Article | Year |
|---|---|
Management of vasospastic angina--role of nicorandil.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Coronary Vasospasm; Humans; Niacinamide; Nicorandil | 1995 |
Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.
Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Hemodynamics; Humans; Myocardial Ischemia; Niacina | 1995 |
Pharmacologic therapy of angina pectoris.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Drug | 1995 |
Prescribing for angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Humans; Myocardial | 1994 |
[Anti-angina activity of potassium-channel activators].
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Humans; Niacinamide; Nicorandil; Potass | 1993 |
A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.
Topics: Angina Pectoris; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Exercise | 1993 |
Nicorandil for angina.
Topics: Angina Pectoris; Humans; Niacinamide; Nicorandil; Vasodilator Agents | 1995 |
[Beta-pyridyl-carbinol in the treatment of hyperlipoproteinemia].
Topics: Angina Pectoris; Delayed-Action Preparations; Drug Evaluation; Drug Tolerance; Humans; Hypercholeste | 1979 |
Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
Topics: Angina Pectoris; Animals; Biological Availability; Drug Interactions; Drug Tolerance; Hemodynamics; | 1992 |
Pharmacology and therapeutic effects of nicorandil.
Topics: Angina Pectoris; Animals; Coronary Vessels; Drug Interactions; Hemodynamics; Humans; Niacinamide; Ni | 1990 |
Nicorandil: animal pharmacology.
Topics: Angina Pectoris; Animals; Coronary Vasospasm; Dogs; Drug Tolerance; Niacinamide; Nicorandil; Vasodil | 1989 |
22 trials available for niacinamide and Angina Pectoris
| Article | Year |
|---|---|
Coronary microvascular response to intracoronary administration of nicorandil.
Topics: Adult; Aged; Angina Pectoris; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Coronary | 1995 |
A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.
Topics: Aged; Angina Pectoris; Coronary Circulation; Coronary Disease; Diltiazem; Dose-Response Relationship | 1993 |
A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Coronary Circulation; Coronary Disease; Double-Blin | 1993 |
A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Exerc | 1993 |
Coronary dilating effects of intracoronary nicorandil. Comparison with isosorbide dinitrate.
Topics: Angina Pectoris; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Coronary Circulation; Coronary V | 1995 |
[Effects of nicorandil on coronary collateral circulation depend on the donor arteries].
Topics: Adult; Aged; Angina Pectoris; Collateral Circulation; Coronary Circulation; Exercise Test; Female; H | 1996 |
[Clinical use of potassium channel activators in angina pectoris: efficacy and tolerance].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Cross-Over Studies; Dose-Response Relationship, Drug; | 1995 |
Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina.
Topics: Administration, Oral; Aged; Angina Pectoris; Coronary Angiography; Cross-Over Studies; Double-Blind | 1997 |
Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
Topics: Angina Pectoris; Animals; Biological Availability; Drug Interactions; Drug Tolerance; Hemodynamics; | 1992 |
Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
Topics: Angina Pectoris; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Exercise; Heart | 1992 |
Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Double-Blind Method; Electrocardiogr | 1992 |
Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy.
Topics: Administration, Oral; Administration, Sublingual; Angina Pectoris; Drug Administration Schedule; Dru | 1992 |
[A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate].
Topics: Aged; Angina Pectoris; Double-Blind Method; Exercise Test; Humans; Isosorbide Dinitrate; Male; Middl | 1991 |
Comparison of nicorandil and atenolol in stable angina pectoris.
Topics: Angina Pectoris; Atenolol; Drug Administration Schedule; Electrocardiography; Exercise Test; Female; | 1990 |
Pharmacology and therapeutic effects of nicorandil.
Topics: Angina Pectoris; Animals; Coronary Vessels; Drug Interactions; Hemodynamics; Humans; Niacinamide; Ni | 1990 |
Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Male; | 1987 |
Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Hemodynamics; Humans; Male; M | 1989 |
A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Dose-Response Relation | 1989 |
Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Double-Blind Metho | 1989 |
Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Diltiazem; Exercise Test; Female; Hemodynamics; Hu | 1989 |
Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Female; Humans; Male; Middle Aged; Niacinamide; Nicor | 1986 |
Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study.
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Hemodyn | 1986 |
22 other studies available for niacinamide and Angina Pectoris
| Article | Year |
|---|---|
[Nicorandil and ulceration: a physiopathological hypothesis].
Topics: Angina Pectoris; Drug Eruptions; Humans; NAD; NADP; Niacin; Niacinamide; Nicorandil; Skin; Skin Ulce | 2012 |
[Studies on the relation between collateral development and the effects of antianginal drugs--effects of nitroglycerin and 2-nicotinamidethyl nitrate on collateral circulation (author's transl)].
Topics: Angina Pectoris; Animals; Collateral Circulation; Coronary Circulation; Dogs; Niacinamide; Nicorandi | 1981 |
Effects of N-(2-hydroxyethyl)nicotinamide nitrate (SG-75) on methacholine-induced ECG changes in intact anesthetized rats.
Topics: Acetylcholine; Anesthesia; Angina Pectoris; Animals; Blood Pressure; Brain; Electrocardiography; Hea | 1981 |
Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris.
Topics: Administration, Oral; Aged; Angina Pectoris; Blood Pressure; Energy Metabolism; Exercise; Female; He | 1995 |
Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angina Pectoris; Animals; Aorta; Cyclic AMP; Cyclic GMP; Drug S | 1995 |
[Therapeutic application of myocardial cytoprotection].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Carnitine; Hum | 1994 |
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
Topics: Angina Pectoris; Animals; Benzoxazines; Blood Pressure; Hemodynamics; Hypotension; In Vitro Techniqu | 1995 |
Evaluation of the efficacy of nicorandil in patients with ischemic heart disease by exercise Tl-201 myocardial SPECT.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Ag | 1994 |
Effect of KRN2391, a novel vasodilator, on various experimental anginal models in rats.
Topics: Angina Pectoris; Animals; Disease Models, Animal; Electrocardiography; Injections, Intravenous; Isop | 1993 |
Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Coronary Circulation; Drug Monitoring; Electrocardi | 1993 |
Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Circu | 1993 |
Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiaze | 1996 |
Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms.
Topics: Adult; Aged; Angina Pectoris; Coronary Angiography; Coronary Circulation; Exercise Test; Female; Hea | 1995 |
Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscle.
Topics: Adenosine Triphosphate; Adult; Aged; Angina Pectoris; Benzopyrans; Cromakalim; Female; Guanidines; H | 1997 |
Effect of JTV-506, a novel vasodilator, on experimental angina model in rats.
Topics: Administration, Oral; Angina Pectoris; Animals; Arginine Vasopressin; Blood Pressure; Chromans; Crom | 1998 |
Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function.
Topics: Angina Pectoris; Cardiac Catheterization; Cardiac Pacing, Artificial; Coronary Disease; Female; Hear | 1987 |
A symposium: A new treatment for angina pectoris and heart failure. October 17, 1987, San Francisco. Proceedings.
Topics: Angina Pectoris; Animals; Heart Failure; Humans; Niacinamide; Nicorandil; Vasodilator Agents | 1989 |
Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris.
Topics: Adult; Angina Pectoris; Electrocardiography; Exercise; Female; Hemodynamics; Humans; Male; Middle Ag | 1989 |
[Influence of antianginal drugs on Lypressin induced T-wave enhancement in the electrocardiogram of the rat].
Topics: Administration, Oral; Angina Pectoris; Animals; Coronary Vasospasm; Electrocardiography; Hypoxia; Is | 1986 |
Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Diltiazem; Drug Resistance; Drug Therapy, Combination; Fem | 1987 |
Protective effects of the antianginal agent nicorandil on arachidonate-induced sudden death in rats: comparison with several antianginal agents and cyclooxygenase inhibitors.
Topics: Angina Pectoris; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Cyclooxygenase Inhibitors; D | 1985 |
[Use of neuroleptoanalgesia with thalamonal in myocardial infarct patients during the painful period].
Topics: Adult; Aged; Angina Pectoris; Benperidol; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1969 |